Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology·2003
Same author

Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.

Protein expression and purification·2001
Same author

Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.

Archives of neurology·2001
Same author

Interactions between the sympathetic nervous system and the immune system.

Brain, behavior, and immunity·1999
Same author

Immunologic therapy of multiple sclerosis.

Annual review of medicine·1999
Same author

Cytokine secretion by deltagamma and alphabeta T cells in monophasic experimental autoimmune encephalomyelitis.

Journal of autoimmunity·1999

Related Experiment Video

Updated: Jul 10, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Treatment of multiple sclerosis with interferon beta.

B G Arnason1

  • 1Department of Neurology, University of Chicago, IL 60637, USA.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|November 11, 1999
PubMed
Summary

Recombinant interferon beta (IFN-b) treatment favorably impacts multiple sclerosis (MS) by reducing attacks and slowing disability progression. While generally safe and well-tolerated, its partial effectiveness highlights the need for improved MS therapies.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: Jul 10, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic immune-mediated disease affecting the central nervous system.
  • Interferon beta (IFN-b) is a key cytokine involved in immune modulation.
  • Understanding the therapeutic potential of IFN-b in MS is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant interferon beta (IFN-b) in managing the natural history of multiple sclerosis.
  • To assess the impact of IFN-b on clinical outcomes and magnetic resonance imaging (MRI) findings in MS patients.

Main Methods:

  • Administration of recombinant interferon beta (IFN-b) via subcutaneous or intramuscular routes.
  • Monitoring of clinical parameters including attack frequency, severity, and disability progression.
  • Utilizing MRI to assess changes in brain lesions and overall disease burden.

Main Results:

  • IFN-b treatment significantly reduced attack frequency and severity in MS patients.
  • A notable slowing in the progression of accumulating disability was observed.
  • MRI revealed a reduction in accumulating permanent disease burden and up to an 80% decrease in newly active white matter lesions, many of which were subclinical.

Conclusions:

  • Recombinant interferon beta (IFN-b) demonstrates favorable effects on the natural history of multiple sclerosis, improving clinical outcomes and reducing MRI-defined disease activity.
  • The drug is generally well-tolerated, with common side effects including transient flu-like symptoms and local injection site reactions.
  • Despite its benefits, IFN-b therapy is only partially effective, underscoring the ongoing need for more effective treatments for multiple sclerosis.